Progenics Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Progenics Pharmaceuticals Inc (PGNX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Progenics Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 37M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-65.5% annualized vs trailing 12 months).
- Peer revenue share: Progenics Pharmaceuticals Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PGNX Sales vs. its Competitors, Q1 2018
Progenics Pharmaceuticals Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 35.9% for Progenics Pharmaceuticals Inc. Progenics Pharmaceuticals Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Progenics Pharmaceuticals Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Progenics Pharmaceuticals Inc | - | Yes | Yes | No |
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PGNX Stock Performance relative to its Competitors
PGNX Stock Performance relative to High-Confidence Competitors
Progenics Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from Progenics Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Qsam Biosciences Inc | Company report | 85% |
| Ge Healthcare Technologies Inc | Company report | 85% |
| Monopar Therapeutics Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Actinium Pharmaceuticals Inc | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Progenics Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.